11:00 AM EDT
San Francisco, CA
17:00 Eastern Time
Conference ID: 8288857
Dr. Jonathan Zalevsky, Chief Research & Development officer discusses bempegaldesleukin (NKTR-214)
We are focused on using new chemistry approaches to make better medicines to treat cancer and auto-immune disease.